ATE447617T1 - Verwendung von rekombinanten proteinen in menschlichen zellen - Google Patents

Verwendung von rekombinanten proteinen in menschlichen zellen

Info

Publication number
ATE447617T1
ATE447617T1 AT05100732T AT05100732T ATE447617T1 AT E447617 T1 ATE447617 T1 AT E447617T1 AT 05100732 T AT05100732 T AT 05100732T AT 05100732 T AT05100732 T AT 05100732T AT E447617 T1 ATE447617 T1 AT E447617T1
Authority
AT
Austria
Prior art keywords
recombinant proteins
human
human cells
compositions
proteins
Prior art date
Application number
AT05100732T
Other languages
German (de)
English (en)
Inventor
Guus Hateboer
Karina Cornelia Verhulst
Govert Schouten
Alphonsus Uytdehaag
Abraham Bout
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE447617(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE447617T1 publication Critical patent/ATE447617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05100732T 1999-04-15 2000-04-17 Verwendung von rekombinanten proteinen in menschlichen zellen ATE447617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201176 1999-04-15
EP99204434 1999-12-21

Publications (1)

Publication Number Publication Date
ATE447617T1 true ATE447617T1 (de) 2009-11-15

Family

ID=26153302

Family Applications (3)

Application Number Title Priority Date Filing Date
AT05100732T ATE447617T1 (de) 1999-04-15 2000-04-17 Verwendung von rekombinanten proteinen in menschlichen zellen
AT00921175T ATE289354T1 (de) 1999-04-15 2000-04-17 Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
AT09174441T ATE536417T1 (de) 1999-04-15 2000-04-17 Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT00921175T ATE289354T1 (de) 1999-04-15 2000-04-17 Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen.
AT09174441T ATE536417T1 (de) 1999-04-15 2000-04-17 Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein

Country Status (18)

Country Link
EP (3) EP2163640B1 (enExample)
JP (1) JP4210036B2 (enExample)
CN (1) CN100457914C (enExample)
AT (3) ATE447617T1 (enExample)
AU (1) AU772352B2 (enExample)
CA (1) CA2370477C (enExample)
CY (1) CY1109759T1 (enExample)
DE (2) DE60043273D1 (enExample)
DK (3) DK2163640T3 (enExample)
ES (3) ES2335775T3 (enExample)
HK (1) HK1048138B (enExample)
IL (2) IL145849A0 (enExample)
MX (1) MXPA01010360A (enExample)
NO (1) NO328951B1 (enExample)
NZ (1) NZ514951A (enExample)
PT (2) PT1161548E (enExample)
SI (2) SI1533380T1 (enExample)
WO (1) WO2000063403A2 (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2003048197A1 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
BR0213402A (pt) * 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CA2468957C (en) 2001-12-07 2011-07-12 Crucell Holland B.V. Methods of propagation of influenza virus in cell lines over expressing sialyl transferases
SI1456238T1 (sl) * 2001-12-17 2008-08-31 Crucell Holland Bv Proizvodnja f(ab)2 fragmentov v sesalskih celicah
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
DE60313125T2 (de) * 2002-01-09 2007-12-20 Crucell Holland B.V. Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
ATE477276T1 (de) 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EA008670B1 (ru) 2003-05-09 2007-06-29 Круселл Холланд Б.В. Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
ATE469920T1 (de) * 2003-05-23 2010-06-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
EP1639009B1 (en) 2003-05-30 2013-02-27 Merus B.V. Fab library for the preparation of a mixture of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
EP1508576A1 (en) * 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
HRP20130616T1 (en) 2003-10-02 2013-08-31 Crucell Holland B.V. Packaging cells for recombinant adenovirus
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
EP1720972B1 (en) * 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
DK1749029T3 (da) 2004-05-27 2011-06-06 Crucell Holland Bv Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
EP2279749B1 (en) 2004-10-12 2015-06-10 Crucell Holland B.V. Binding molecules for detection of aml
KR101271884B1 (ko) 2004-11-08 2013-06-05 크로마제닉스 비.브이. 고수준으로 단백질을 발현하는 숙주세포의 선택
EP1812067B1 (en) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007055916A2 (en) * 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
EP1996705B1 (en) 2006-03-20 2011-08-31 ChromaGenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
US10167332B2 (en) * 2006-04-05 2019-01-01 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2024394B1 (en) 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2654712C (en) 2006-06-06 2015-05-05 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
PL2343362T5 (pl) 2006-07-14 2024-12-02 Patheon Holdings I B.V. Ulepszony proces hodowli komórek
DK2059532T3 (da) 2006-09-07 2013-03-18 Crucell Holland Bv Humane bindingsmolekyler, der er i stand til at neutralisere influenzavirus H5N1, og anvendelser deraf
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
EP3176263A1 (en) 2007-08-10 2017-06-07 Toto Ltd. Method of producing recombinant mammalian cells
EP2222694B1 (en) * 2007-12-13 2014-01-15 Roche Diagnostics GmbH Novel rubella e1 envelope protein variants and their use in the detection of anti-rubella antibodies
WO2009126308A2 (en) * 2008-04-11 2009-10-15 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for vaccine and virus production
MX2010011598A (es) 2008-04-22 2010-12-15 Univ Rockefeller Metodos para identificar compuestos anti-inflamatorios.
ES2558436T3 (es) * 2008-07-15 2016-02-04 Crucell Holland B.V. Proceso escalable para cultivar células PER.C6 y producir productos a partir de estas
UA108735C2 (uk) 2008-07-21 2015-06-10 Структурні варіанти антитіл для покращення терапевтичних характеристик
US8357661B2 (en) 2009-04-23 2013-01-22 Crucell Holland B.V. Recombinant human Alpha1-antitrypsin
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
JP4998814B2 (ja) 2009-10-01 2012-08-15 Ｔｏｔｏ株式会社 Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
DK2731967T3 (en) 2011-07-14 2017-01-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN102827273A (zh) * 2012-02-16 2012-12-19 张小莺 抗痘苗病毒IgY抗体的制备
DK2822968T3 (en) 2012-03-08 2018-04-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
US9657290B2 (en) 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
EP2900692A1 (en) 2012-09-27 2015-08-05 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
DK2900694T3 (en) 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
EP2986638A1 (en) 2013-04-15 2016-02-24 Crucell Holland B.V. Human antibodies binding to rsv g proteins
CA2908878C (en) 2013-04-15 2021-06-29 Crucell Holland B.V. Human antibodies binding to rsv g protein
DE112014003136A5 (de) 2013-07-01 2016-04-21 Charité - Universitätsmedizin Berlin Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
CN104693308B (zh) * 2013-12-05 2020-08-04 同济大学 感受胞内pH变化的Smad5蛋白及其应用
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
PH12017501216B1 (en) 2015-02-05 2023-05-24 Janssen Vaccines And Prevention B V Binding molecules directed against influenza hemagglutinin and uses thereof
EP3253787B1 (en) 2015-02-05 2020-10-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
WO2016134370A1 (en) 2015-02-22 2016-08-25 The Board Of Trustees Of The Leland Stanford Junior University Micro-screening apparatus, process, and products
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP7010811B2 (ja) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ ヒトｃｄ３結合抗体
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
EP3423484B1 (en) 2016-03-01 2021-01-13 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza b neuraminidase
CN115254210A (zh) 2016-11-14 2022-11-01 浩康生物系统公司 用于分选目标颗粒的方法和装置
CN110418804A (zh) 2017-03-28 2019-11-05 扬森疫苗与预防公司 与tau特异性地结合的结合分子
EP3600413A1 (en) 2017-03-31 2020-02-05 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
WO2018192974A1 (en) 2017-04-18 2018-10-25 Université Libre de Bruxelles Biomarkers and targets for proliferative diseases
KR102744809B1 (ko) 2017-05-17 2024-12-23 메뤼스 엔.페. 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합
PL3665198T3 (pl) 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
TW201930351A (zh) 2017-10-06 2019-08-01 日商小野藥品工業股份有限公司 雙特異性抗體
EP3720490A1 (en) 2017-12-04 2020-10-14 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2019149798A1 (en) 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
KR102879500B1 (ko) 2018-03-23 2025-10-31 유니베르시테 리브레 드 브룩크젤즈 Wnt 시그널링 작용제 분자
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
KR20220039720A (ko) 2019-07-30 2022-03-29 오노 야꾸힝 고교 가부시키가이샤 이중 특이성 항체
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
CN117441021A (zh) * 2021-06-11 2024-01-23 孟山都技术有限公司 用于改变蛋白积聚的方法和组合物
TW202417488A (zh) 2022-08-23 2024-05-01 日商小野藥品工業股份有限公司 雙特異性抗體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
GB8900483D0 (en) * 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
ES2100953T3 (es) * 1991-08-01 1997-07-01 Fond Nat Transfusion Sanguine Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.
CZ287157B6 (en) * 1993-07-13 2000-10-11 Rhone Poulenc Rorer Sa Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
US5610043A (en) * 1994-04-28 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
EP1445322B2 (en) * 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Also Published As

Publication number Publication date
DK1533380T3 (da) 2010-02-01
NO328951B1 (no) 2010-06-28
SI1533380T1 (sl) 2010-03-31
ES2237420T3 (es) 2005-08-01
MXPA01010360A (es) 2004-04-05
IL145849A (en) 2009-07-20
CA2370477A1 (en) 2000-10-26
CN100457914C (zh) 2009-02-04
CN1360638A (zh) 2002-07-24
DE60018171T2 (de) 2005-12-29
EP1533380B1 (en) 2009-11-04
EP1161548A2 (en) 2001-12-12
EP1533380A3 (en) 2005-06-22
DE60018171D1 (de) 2005-03-24
NO20014977L (no) 2001-12-17
NZ514951A (en) 2004-02-27
WO2000063403A2 (en) 2000-10-26
PT1533380E (pt) 2010-02-09
AU4152000A (en) 2000-11-02
EP1161548B1 (en) 2005-02-16
HK1048138B (zh) 2009-06-12
ES2378272T3 (es) 2012-04-10
EP2163640B1 (en) 2011-12-07
HK1048138A1 (zh) 2003-03-21
DE60043273D1 (de) 2009-12-17
EP1161548B2 (en) 2009-10-14
EP2163640A1 (en) 2010-03-17
PT1161548E (pt) 2005-06-30
DK2163640T3 (da) 2012-03-05
AU772352B2 (en) 2004-04-22
ES2335775T3 (es) 2010-04-05
CA2370477C (en) 2010-06-29
ES2237420T5 (es) 2010-03-03
SI1161548T1 (en) 2005-08-31
EP1533380A2 (en) 2005-05-25
ATE536417T1 (de) 2011-12-15
IL145849A0 (en) 2002-07-25
ATE289354T1 (de) 2005-03-15
JP2002541854A (ja) 2002-12-10
DK1161548T4 (da) 2010-03-01
WO2000063403A3 (en) 2001-02-15
DK1161548T3 (da) 2005-05-23
SI1161548T2 (sl) 2010-02-26
DE60018171T3 (de) 2010-05-20
CY1109759T1 (el) 2014-09-10
NO20014977D0 (no) 2001-10-12
JP4210036B2 (ja) 2009-01-14

Similar Documents

Publication Publication Date Title
ATE447617T1 (de) Verwendung von rekombinanten proteinen in menschlichen zellen
BRPI0417916A (pt) proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
DK0851868T3 (da) Höjniveau-ekspression af proteiner
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
BRPI0507159A (pt) polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
SE9901379D0 (sv) Receptor structures
DK0929564T3 (da) Höjniveau-ekspression af proteiner
PT1969007E (pt) Composições e métodos para a produção de uma composição
EA200602163A1 (ru) Способы и средства получения белков с заранее заданными посттрансляционными модификациями
CY1107556T1 (el) Συνθεσεις αναλογων g-csf και μεθοδοι
DE69920747D1 (de) Methode zur herstellung von rekombinanten zellen
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
PT902085E (pt) Eritropoietina humana recombinante com perfil de glicosilacao vantajoso
BR9909639A (pt) Processos para reduzir a alergenicidade de uma proteìna não humana e para produzir uma proteìna tendo reduzida alergenicidade, proteìna mutante tendo reduzida alergenicidade, dna, vetor de expressão, células hospedeiras, composição farmacêutica, e, substilisina humana
CY1109167T1 (el) Μεθοδος για την παρασκευη αυξητικης ορμονης και ανταγωνιστη αυτης εχοντας χαμηλοτερα επιπεδα ισομορφικων προσμειξεων αυτου
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
ATE414762T1 (de) Herstellung kultivierter menschlicher mastzellen und basophilen zur hochdurchsatz-entdeckung kleiner arzneistoffmoleküle
ATE386054T1 (de) Glycosylierte humane interferon alpha isoform
KR930008148A (ko) 변이 인간 프로우로키나아제
RU2008150348A (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
BR9704975A (pt) Eritropoetina humana recombinante obtida com uma atividade biológica in vivo superior por expressão em linhagem de célula de ovário de hamster chinês
KR960023061A (ko) 재조합 인간 적혈구생성 촉진인자의 제조방법, 이를 위한 벡터 및 동물 세포주
BR0206638B1 (pt) processo de regulação de uma célula de eletrólise

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1533380

Country of ref document: EP